Lymphoma & Myeloma 2015


Lymphoma & Myeloma 2015 was held October 22 - 24 in New York City.


Breast cancer drug may also work in MCL, myeloma

Erilyn Riley Read Article
Published: 11/06/15

Bone marrow aspirate
showing multiple myeloma

Targeting the cell cycle with cyclin-dependent kinase (CDK) inhibitors may be an effective strategy to treat lymphoma and myeloma, according to a presentation at Lymphoma & Myeloma 2015. Palbociclib, an inhibitor of CDK4 and CDK6, received accelerated approval from the US Food and Drug Administration to treat advanced breast cancer. Now, it is showing promise in mantle cell lymphoma (MCL) and multiple myeloma (MM) as well. [Read Article]

Post-ibrutinib management in MCL unclear, speaker says

Erilyn Riley Read Article
Published: 11/03/15

Mantle cell lymphoma

Despite an “unprecedented” single-agent response rate and progression-free survival (PFS) in previously treated mantle cell lymphoma (MCL) patients, those with multiple risk factors have a dismal outcome following ibrutinib failure. So after ibrutinib, what’s next in MCL? That was the question asked at Lymphoma & Myeloma 2015. Peter Martin, MD, of Weill Cornell Medical College, discussed some possibilities. [Read Article]

Reprogramming the immune system

Erilyn Riley Read Article
Published: 11/01/15

Electron micrograph
showing Hodgkin lymphoma

Using a 3-pronged approach to reprogram the immune system—inhibition of critical pathways, activation of others, and depletion of malignant cells—may be the best strategy to optimize immune function in B-cell lymphomas, according to Stephen M. Ansell, MD, PhD, of the Mayo Clinic in Rochester, Minnesota.“[A]ll told, there are multiple immunological barriers to an effective immune response,” Dr Ansell said at Lymphoma & Myeloma 2015. [Read Article]

Median DOR, PFS not yet reached for ibrutinib in CLL

Erilyn Riley Read Article
Published: 10/30/15

Ibrutinib (Imbruvica) capsules
Photo courtesy of
Janssen Biotech, Inc.

Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms that the Bruton’s tyrosine kinase inhibitor produces rapid and durable responses in patients with chronic lymphocytic leukemia (CLL), according to an update presented at Lymphoma & Myeloma 2015. At up to 44 months of follow-up, the median duration of response (DOR) and progression-free survival (PFS) have not yet been reached. [Read Article]

The search continues for additional targets in CLL

Erilyn Riley Read Article
Published: 10/29/15

Peripheral blood smear
showing CLL
Image by Mary Ann Thompson

Despite enormous advances in therapies for chronic lymphocytic leukemia (CLL) that target the B-cell receptor (BCR) signaling pathway, there is still room for improvement, according to investigators at the Mayo Clinic. Bruton’s tyrosine kinase (BTK) and phosphoinositide-3 kinase delta (PI3Kδ) inhibitors are major players in mediating BCR signaling, yet both have off-target effects. [Read Article]

Ibrutinib may prove useful in MM, research shows

Erilyn Riley Read Article
Published: 10/28/15

Bone marrow aspirate
showing multiple myeloma

Results of an open-label, phase 2, dose-escalation study of ibrutinib combined with low-dose dexamethasone suggest the Bruton’s tyrosine kinase (BTK) inhibitor may be useful in treating relapsed or relapsed and refractory patients with multiple myeloma (MM). In the highest dose cohort, 23% of patients experienced a clinical benefit, which was defined as a minimal response or better by International Myeloma Working Group criteria. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}